276 related articles for article (PubMed ID: 27846755)
1. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
[TBL] [Abstract][Full Text] [Related]
2. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
5. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
6. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis.
Çakan M; Karadağ ŞG; Tanatar A; Ayaz NA
Mod Rheumatol; 2020 Sep; 30(5):900-904. PubMed ID: 31462146
[No Abstract] [Full Text] [Related]
7. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
8. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
Sukharomana M; Udomittipong K; Ruangchira-Urai R; Charuvanij S
Asian Pac J Allergy Immunol; 2022 Jun; 40(2):172-176. PubMed ID: 31837211
[TBL] [Abstract][Full Text] [Related]
9. Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
Wagner-Weiner L
Pediatr Ann; 2015 Jun; 44(6):e142-7. PubMed ID: 26114369
[TBL] [Abstract][Full Text] [Related]
10. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Yasin S; Fall N; Brown RA; Henderlight M; Canna SW; Girard-Guyonvarc'h C; Gabay C; Grom AA; Schulert GS
Rheumatology (Oxford); 2020 Feb; 59(2):361-366. PubMed ID: 31326996
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
Sakumura N; Shimizu M; Mizuta M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2018 Oct; 110():459-465. PubMed ID: 29801971
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
[TBL] [Abstract][Full Text] [Related]
13. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
[TBL] [Abstract][Full Text] [Related]
14. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
Hinze T; Kessel C; Hinze CH; Seibert J; Gram H; Foell D
Rheumatology (Oxford); 2021 Nov; 60(11):5165-5174. PubMed ID: 33576397
[TBL] [Abstract][Full Text] [Related]
15. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
[No Abstract] [Full Text] [Related]
16. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
Gupta A; Bagri NK; Tripathy SK; Barwad A; Phulware RH; Hari P
Rheumatol Int; 2020 Jan; 40(1):153-159. PubMed ID: 31273457
[TBL] [Abstract][Full Text] [Related]
17. Systemic Juvenile Idiopathic Arthritis.
Lee JJY; Schneider R
Pediatr Clin North Am; 2018 Aug; 65(4):691-709. PubMed ID: 30031494
[TBL] [Abstract][Full Text] [Related]
18. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
[TBL] [Abstract][Full Text] [Related]
19. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Likhacheva TS; Isupova EA; Glebova NI; Kuchinskaya EM; Balbotkina EV; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Semin Arthritis Rheum; 2015 Feb; 44(4):417-22. PubMed ID: 25300700
[TBL] [Abstract][Full Text] [Related]
20. PRECORDIAL PAIN, LEUKOCYTOSIS AND BICYTOPENIA IN A TEENAGER WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS UNDER IMMUNOSUPPRESSIVE THERAPY.
Vieira MS; Andrade FR; Brandão LMKR; Nóbrega VTD; Guissa VR; Provenza JR
Rev Paul Pediatr; 2019; 37(2):252-256. PubMed ID: 30810692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
